ASKA Pharmaceutical Co., Ltd. Stock Japan Exchange
Stocks
4514
JP3541200006
Pharmaceuticals
OTC Markets Traded
| Market Cap | 64.49B 399M 351M 324M 303M 567M 37.57B 578M 3.89B 1.51B 18.54B 1.5B 1.46B | P/E 2026 |
12.3x | P/E 2027 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise Value | 64.49B 399M 351M 324M 303M 567M 37.57B 578M 3.89B 1.51B 18.54B 1.5B 1.46B | EV / Sales 2026 |
0.94x | EV / Sales 2027 * | 0.91x |
| Free-Float |
61.83% | Yield 2026 |
2.54% | Yield 2027 * | 2.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tomohito Nagao
CEO | Chief Executive Officer | - | - |
Sota Yamaguchi
PSD | President | 42 | 2025-06-23 |
Kiyohiko Tamura
ADM | Chief Administrative Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 2025-06-23 | |
Atsushi Maruo
BRD | Director/Board Member | 67 | 2021-03-31 |
Yasuji Enokido
BRD | Director/Board Member | 66 | 2023-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -4.29% | - | - | 400M | |
| -0.20% | -0.92% | +41.61% | +143.36% | 987B | |
| +0.13% | +1.98% | +56.94% | +45.96% | 576B | |
| -0.56% | +5.42% | +25.69% | +72.81% | 415B | |
| +3.61% | -1.30% | +22.76% | +15.66% | 320B | |
| +2.35% | +3.25% | +34.63% | +23.18% | 278B | |
| +0.75% | +2.76% | +30.31% | +39.83% | 279B | |
| +1.23% | +9.11% | -31.23% | -42.04% | 208B | |
| +1.10% | +2.57% | +26.29% | +55.94% | 187B | |
| +0.29% | -0.06% | +16.96% | +63.77% | 155B | |
| Average | +0.90% | +1.51% | +24.88% | +46.50% | 378.36B | |
| Weighted average by Cap. | +0.66% | +0.73% | +32.58% | +68.25% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 69.09B 427M 376M 347M 324M 608M 40.25B 619M 4.17B 1.61B 19.86B 1.6B 1.57B | 71.06B 439M 387M 357M 334M 625M 41.41B 637M 4.29B 1.66B 20.43B 1.65B 1.61B |
| Net income | 5.19B 32.06M 28.23M 26.04M 24.35M 45.63M 3.02B 46.48M 313M 121M 1.49B 120M 118M | 5.6B 34.64M 30.49M 28.13M 26.31M 49.29M 3.26B 50.21M 338M 131M 1.61B 130M 127M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
